A detailed history of Wellington Management Group LLP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 106,025 shares of CGEM stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
106,025
Previous 72,098 47.06%
Holding current value
$1.47 Million
Previous $1.26 Million 41.13%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.03 - $20.86 $543,849 - $707,717
33,927 Added 47.06%
106,025 $1.77 Million
Q2 2024

Aug 13, 2024

BUY
$15.63 - $29.35 $58,456 - $109,769
3,740 Added 5.47%
72,098 $1.26 Million
Q1 2024

May 15, 2024

BUY
$10.17 - $19.02 $695,200 - $1.3 Million
68,358 New
68,358 $1.16 Million
Q1 2023

May 12, 2023

BUY
$10.2 - $11.91 $2,356 - $2,751
231 Added 0.86%
27,122 $277,000
Q4 2022

Feb 13, 2023

BUY
$9.72 - $13.62 $5,414 - $7,586
557 Added 2.12%
26,891 $283,000
Q3 2022

Nov 14, 2022

SELL
$11.82 - $15.42 $5,496 - $7,170
-465 Reduced 1.74%
26,334 $337,000
Q2 2022

Aug 15, 2022

BUY
$7.31 - $13.55 $2,945 - $5,460
403 Added 1.53%
26,799 $344,000
Q1 2022

May 16, 2022

SELL
$10.47 - $16.75 $190,302 - $304,448
-18,176 Reduced 40.78%
26,396 $277,000
Q4 2021

Feb 11, 2022

BUY
$15.36 - $25.0 $684,625 - $1.11 Million
44,572 New
44,572 $688,000
Q2 2021

Aug 16, 2021

SELL
$24.96 - $41.25 $3.86 Million - $6.37 Million
-154,539 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$28.0 - $53.42 $4.33 Million - $8.26 Million
154,539 New
154,539 $6.44 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $632M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.